Please login to the form below
heart failure
This page shows the latest heart failure news and features for those working in and with pharma, biotech and healthcare.
AZ finally gets EU nod for Veltassa rival Lokelma
The risk of hyperkalaemia increases significantly for patients with chronic kidney disease (CKD) and for those who take certain heart failure (HF) medicines that increase potassium levels in the blood. ... The consequences of hyperkalaemia can be serious,
Latest news
-
Novartis negotiates ex-US rights to Spark gene therapy
The gains were driven by strong performances from new immunotherapy Cosentyx (secukinumab), which breached the $2bn sales threshold for the year, as well as heart failure therapy Entresto (sacubitril and valsartan)
-
Celixir cleared to start trial of stem cell therapy for heart failure
Heart failure is still a major cause of death affecting millions of patients worldwide [and] current therapies do not reduce chronic myocardial scarring, diminish disease progression or prolong life, ”commented Prof ... We are assembling a world-class
-
Joerg Moeller to head Bayer R&D after operational shake-up
testing, vericiguat and neladenoson bialanate for heart failure, and progress in gynaecology with six candidates in clinical development for uterine fibroids and endometriosis.
-
First patient treated with Sangamo’s gene-editing tech
in turn cause symptoms such as hearing loss, declining heart function, an enlarged liver and spleen and joint stiffness. ... Many patients with MPS II die of airway obstruction, upper respiratory infection or heart failure before they reach the age of 20.
-
Alcon spin-out more likely but not imminent, says Novartis
Alcon re-emerged as one of the engines of Novartis’growth in the third quarter along with fast-growing psoriasis blockbuster Cosentyx (secukinumab) and heart failure therapy Entresto (sacubitril/valsartan), which
More from news
Approximately 33 fully matching, plus 220 partially matching documents found.
Latest Intelligence
-
No incentive for a cure
Type 1 diabetes, heart failure, HIV - all examples of diseases that have transitioned from fatal conditions to chronic diseases, thanks to the progress in modern medicine.
-
Can value-based healthcare take off and reach for the skies?
costs. It was then backed with a ‘no response-no payment’contract. It has also struck novel reimbursement packages with its heart failure therapy Entresto and its psoriasis treatment Cosentyx.
-
Deal Watch February 2017
Sale of Priority Review Voucher (PRV). 125. Cytokinetics/ Royalty Pharma. 4.5% royalty on global sales of omecamtiv mecarbil for heart failure (phase III).
-
Deal Watch January 2017
1, 700. Ionis | Akcea. Novartis. Exclusive option to licence. AKCEA-APOCIII-LRx for heart failure.
-
A healthy challenge
All told, 50 million people in the EU are afflicted by conditions such as diabetes, congestive heart failure, chronic obstructive pulmonary disease and asthma, and in 2013 more than 1.2m
More from intelligence
Approximately 1 fully matching, plus 18 partially matching documents found.
Latest appointments
-
uniQure appoints chief executive officer
for congestive heart failure and Huntington's disease into the clinic.”.
-
Cardio3 BioSciences appoints Warren Sherman chief medical officer
Sherman has over 30 years' cardiology experience, with a focus on cell-based therapies for treating patients post-myocardial infarction and with heart failure.
-
Acorda appoints new CFO
pain and heart failure.
-
Cardioxyl appoints Novartis scientist as chief medical officer
Dr Foo was responsible for the establishment and execution of multiple programmes in heart failure and the cardiorenal space at Novartis and will use her experience to lead research at ... Her unique combination of both early- and late-stage
-
CytomX makes senior changes following Pfizer deal
Prior to this period at Affymax, Dr Polu was executive director, global development at Amgen, where he worked in the development of products in nephrology, diabetes and heart failure.
More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest from PMHub
-
Case Study: Qualitative research with payers in low and middle income countries
Our client wanted to understand in detail the usage decision drivers, triggers and processes for a high-cost innovative Acute Heart Failure (AHF) drug used in the acute emergency setting in
More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.
Featured jobs
- FREELANCE Account Manager – Creative Healthcare Advertising – Lo...
-
SUPERB DAY RATES AVAILABLE
- Senior Medical Writer, Medical Communications, Relocate to Cardi...
-
Excellent Salary
-
Scientific Director
-
Great salary and bebefits
- Principal Medical Writer, Medical Communications, Relocate to Ca...
-
Excellent Salary
-
Senior Medical Writer
-
Great salary and bebefits
- Editor > Senior Editor – Medical Education – London
-
Very competitive with excellent benefits
-
Senior Programme Executive
-
Salary TBC
-
Account Manager, Healthcare PR
-
£40, 000 – £42, 000 great benefits and bonuses
- Account Manager – Med Comms – London
-
Salary TBC
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
- Senior Account Manager / Account Director
-
Great salary and bebefits
- Senior Account Manager – Med Comms – Kent
-
Salary TBC
- Senior / Principal Regulatory Writer – Home Working - UK or US
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
- Head of Operations/ BUD, Healthcare PR, London – Excellent leade...
-
Excellent Package
-
Senior Medical Writer
-
Great salary and benefits
- FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...
-
EXCELLENT DAY RATES AVAILABLE
Subscribe to our email news alerts
- Shire warms to Takeda’s latest offer, extending deadline
- Otsuka finally gets FDA OK for kidney disease drug
- Pfizer takes aim at UK’s health tech industry
- Morning brief: Takeda closes in on $64bn merger, GSK unveils team, and more
- It’s nice, but it’s not an infographic
- PureTech Health appoints new chief financial officer
PMHub
3 Monkeys Zeno
3 Monkeys Zeno is the UK arm of Zeno Group, a global integrated communications consultancy. Everything we do is rooted...
Latest intelligence
- Pharma’s isolated islands of innovation
- With service design and technology often failing the patient, why perspective on improving outcomes need to change...
- Uncertainty, austerity and Brexit
- What does it mean for the life science sector?...
- The Holy Grail of HCP Access
- This is the data you need to gain access....
Quick links
Infographics
